This article is more than 5 years old. Information may no longer be current.
'Dropless' cataract surgery a safe alternative to postop topical drops
Click Here to Manage Email Alerts
WASHINGTON — “Dropless” cataract surgery offers an alternative to postoperative drops, according to a speaker here.
A prospective cohort study of 154 eyes of 83 patients who received either a steroid-antibiotic injection during cataract surgery or postoperative drops evaluated the safety of the dropless option, Abdullah Nasser, MD, said during a paper session at the American Society of Cataract and Refractive Surgery annual meeting.
A total of 36 patients chose the dropless option and were administered an intravitreal injection of triamcinolone acetonide and moxifloxacin hydrochloride 3 mg/0.2 mg transzonularly after an IOL was inserted, while 50 patients opted for topical moxifloxacin and dexamethasone drops.
Patients in both groups had no difference in IOP or moderate or severe corneal edema, Nasser said. Dropless patients were more likely to complain of transient floaters postoperatively.
“What we saw was that patients’ outcomes were quite similar,” he said. “Dropless provided a safe alternative to drops. It was move convenient, there were no complications, and it seemed very efficacious.” – by Rebecca L. Forand
Reference:
Nasser A. Dropless cataract surgery: Alternative advanced drug-delivery method for cataract surgery patients. Presented at: American Society of Cataract and Refractive Surgery annual meeting; April 13-17, 2018; Washington.
Disclosure: Nasser reports no relevant financial disclosures.